Multiple field three dimensional quantitative structure-activity relationship (MF-3D-QSAR)

被引:101
作者
Du, Qi-Shi [1 ,2 ,3 ]
Huang, Ri-Bo [1 ,4 ]
Wei, Yu-Tuo [1 ]
Du, Li-Qin [1 ]
Chou, Kuo-Chen [3 ]
机构
[1] Guangxi Univ, Guangxi Key Lab Subtrop Bioresource Conservat & U, Nanning 530004, Guangxi, Peoples R China
[2] Hainan Normal Univ, Dept Chem, Haikou 571158, Hainan, Peoples R China
[3] Gordon Life Sci Inst, San Diego, CA 92130 USA
[4] Guangxi Acad Sci, Nanning 530004, Guangxi, Peoples R China
关键词
3D-QSAR; potential fields; drug design; neuraminidase inhibitor; H5N1; influenza;
D O I
10.1002/jcc.20776
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A new drug design method, the multiple field three-dimensional quantitative structure-activity relationship (MF-3D-QSAR), is proposed. It is a combination and development of classical 2D-QSAR and traditional 3D-QSAR. In addition to the electrostatic and van der Waals potentials, more potential fields (such as lipophilic potential, hydrogen bonding potential, and nonthermodynamic factors) are integrated in the MF-3D-QSAR. Meanwhile, a principal component analysis (PCA) and iterative double least square (IDLS) technique is developed for predicting the bioactivity of query drug candidates. As an example, the MF-3D-QSAR is applied to the design of neuraminidase inhibitor and to prove its predictive power, and some useful findings are obtained for developing drugs against influenza virus. (C) 2007 Wiley Periodicals, Inc.
引用
收藏
页码:211 / 219
页数:9
相关论文
共 33 条
[21]   MOLECULAR SIMILARITY INDEXES IN A COMPARATIVE-ANALYSIS (COMSIA) OF DRUG MOLECULES TO CORRELATE AND PREDICT THEIR BIOLOGICAL-ACTIVITY [J].
KLEBE, G ;
ABRAHAM, U ;
MIETZNER, T .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (24) :4130-4146
[22]   ANTI-MYCOBACTERIUM-AVIUM ACTIVITY OF QUINOLONES - STRUCTURE-ACTIVITY RELATIONSHIP STUDIES [J].
KLOPMAN, G ;
WANG, SM ;
JACOBS, MR ;
ELLNER, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (09) :1807-1815
[23]   ANTI-MYCOBACTERIUM-AVIUM ACTIVITY OF QUINOLONES - IN-VITRO ACTIVITIES [J].
KLOPMAN, G ;
WANG, SM ;
JACOBS, MR ;
BAJAKSOUZIAN, S ;
EDMONDS, K ;
ELLNER, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (09) :1799-1806
[24]   N-1-tert-butyl-substituted quinolones: In vitro anti Mycobacterium avium activities and structure-activity relationship studies [J].
Klopman, G ;
Fercu, D ;
Renau, TE ;
Jacobs, MR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (11) :2637-2643
[25]   Antimycobacterial quinolones: A comparative analysis of structure activity and structure cytotoxicity relationships [J].
Klopman, G ;
Fercu, D ;
Li, JY ;
Rosenkranz, HS ;
Jacobs, MR .
RESEARCH IN MICROBIOLOGY, 1996, 147 (1-2) :86-96
[26]   Discovery and development of GS 4104 (oseltamivir): An orally active influenza neuraminidase inhibitor [J].
Lew, W ;
Chen, XW ;
Kim, CU .
CURRENT MEDICINAL CHEMISTRY, 2000, 7 (06) :663-672
[27]   STRATEGIES FOR INDIRECT COMPUTER-AIDED DRUG DESIGN [J].
LOEW, GH ;
VILLAR, HO ;
ALKORTA, I .
PHARMACEUTICAL RESEARCH, 1993, 10 (04) :475-486
[28]   Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors [J].
Maring, CJ ;
Stoll, VS ;
Zhao, C ;
Sun, MH ;
Krueger, AC ;
Stewart, KD ;
Madigan, DL ;
Kati, WM ;
Xu, YB ;
Carrick, RJ ;
Montgomery, DA ;
Kempf-Grote, A ;
Marsh, KC ;
Molla, A ;
Steffy, KR ;
Sham, HL ;
Laver, WG ;
Gu, YG ;
Kempf, DJ ;
Kohlbrenner, WE .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (12) :3980-3990
[29]   Analysis of inhibitor binding in influenza virus neuraminidase [J].
Smith, BJ ;
Colman, PM ;
Von Itzstein, M ;
Danylec, B ;
Varghese, JN .
PROTEIN SCIENCE, 2001, 10 (04) :689-696
[30]   ANALYSIS OF THE INVITRO ANTITUMOR-ACTIVITY OF NOVEL PURINE-6-SULFENAMIDE, PURINE-6-SULFINAMIDE, AND PURINE-6-SULFONAMIDE NUCLEOSIDES AND CERTAIN RELATED-COMPOUNDS USING A COMPUTER-AIDED RECEPTOR MODELING PROCEDURE [J].
VISWANADHAN, VN ;
GHOSE, AK ;
HANNA, NB ;
MATSUMOTO, SS ;
AVERY, TL ;
REVANKAR, GR ;
ROBINS, RK .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (02) :526-532